Welcome to our dedicated page for HILS news (Ticker: hils), a resource for investors and traders seeking the latest updates and insights on HILS stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect HILS's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of HILS's position in the market.
Hillstream BioPharma (NASDAQ:HILS) has announced significant upcoming events, including a R&D Day on February 24, 2022, and a Business Review on February 14, 2022. The R&D Day will showcase emerging pipeline assets and anticipated milestones, focusing on innovative therapeutic candidates targeting ferroptosis, an anti-cancer mechanism for treating drug-resistant cancers. The company's lead candidate, HSB-1216, showed positive results in a clinical pilot study in Germany, targeting various solid tumors. The company aims to advance HSB-1216 into further clinical trials this year.
Hillstream BioPharma, Inc. (NASDAQ:HILS) announced acceptance of an abstract on HSB-510, a novel dual-targeted HDAC6/PI3K-delta inhibitor, for presentation at the 2022 AACR Annual Meeting. This drug targets ferroptosis to combat drug-resistant cancers, showing promise in preclinical studies by significantly downregulating the growth of triple-negative breast cancer (TNBC) cells. HSB-510 is encapsulated in a proprietary Quatramer formulation with potential for effective therapy targeting multiple MYC-dependent tumors. The company plans IND-enabling studies in 2023.
Hillstream BioPharma (Nasdaq:HILS) has announced a collaboration with University of Massachusetts Chan Medical School aimed at identifying a novel chemogenetic biomarker profile for HSB-1216, its lead anti-cancer compound targeting iron-mediated cell death. This collaboration will leverage CRISPR genome editing to advance the Hillstream Ferroptomic Atlas, enhancing understanding of the drug's effect on drug-resistant tumors. The partnership involves Dr. Michael J. Lee's lab, which specializes in cancer cell signaling pathways. The expected outcomes include insights into the compound's mechanism and potential biomarkers for clinical trials.